---
title: "PRESSURE BIOSCIENCES INC SEC 10-Q Report"
date: "2025-02-08 06:33:00"
summary: "Pressure BioSciences Inc., a leader in the development and sale of innovative solutions for the life sciences industry, has released its Form 10-Q report for the third quarter. The report provides a comprehensive overview of the company's financial performance and operational highlights, reflecting both challenges and strategic initiatives aimed at..."
categories:
  - "TradingView"
lang:
  - "en"
translations:
  - "en"
tags:
  - "TradingView"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Pressure BioSciences Inc., a leader in the development and sale of innovative solutions for the life sciences industry, has released its Form 10-Q report for the third quarter. The report provides a comprehensive overview of the company's financial performance and operational highlights, reflecting both challenges and strategic initiatives aimed at future growth.

**Financial Highlights**

**Total Revenue**: $0.77 million, reflecting a decrease from $1.25 million in the same period last year, primarily due to lower sales in hardware and consumables.

**Gross Margin**: $0.16 million, indicating a reduction in profitability compared to the previous year, driven by increased costs in general and administrative expenses.

**Operating Loss**: $(3.41) million, showing an improvement from $(4.72) million in the prior year, attributed to cost management efforts.

**Net Loss**: $(15.19) million, compared to $(13.78) million in the previous year, impacted by higher interest expenses and deemed dividends.

**Net Loss Per Share**: $(0.36), improved from $(1.04) in the prior year, reflecting the impact of increased weighted average shares outstanding.

**Business Highlights**

**Revenue Segments**

The company reported revenue from various product lines, including hardware, consumables, contract research services, sample preparation accessories, consumer products, technical support/extended service contracts, agrochem products, and shipping and handling. Consumer products, particularly from the Uncle Bud's acquisition, contributed significantly to the revenue.

**Geographical Performance**

The primary geographical markets for the company's products include North America, Europe, and Asia. North America remains the largest market, with significant contributions from consumer product sales.

**Sales Units**

The company has seen an increase in the number of Pressure Cycling Technology (PCT) and Ultra Shear Technology (UST) units installed, which is expected to drive future revenue from consumables and service contracts.

**New Product Launches**

The company continues to develop new instrument and consumable product offerings, especially in the area of Ultra Shear Technology, which is anticipated to have significant commercial potential.

**Future Outlook**

Management expects an increase in the number of PCT and UST units installed, leading to higher revenues from consumables and service contracts. The company is also focusing on expanding its customer base in applications of PCT, BaroFold, and UST products and services.

SEC Filing: [PRESSURE BIOSCIENCES INC [ PBIO ] - 10-Q - Feb. 07, 2025](https://www.sec.gov/Archives/edgar/data/830656/000149315225005468/form10-q.htm)

[TradingView](https://www.tradingview.com/news/tradingview:285c904a67d6a:0-pressure-biosciences-inc-sec-10-q-report/)
